Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk: The Evolution of Bone Health Discourse

The legacy of general health and science information has long served as a foundation for public understanding of medical risks, emphasizing broad awareness of disease prevention and treatment outcomes. Within this heritage, the focus on bone health and metabolic disorders has been a consistent thread, guiding both clinical practice and patient education. As this informational framework evolves, it naturally extends into more specialized domains where therapeutic interventions intersect with unintended consequences. One such area of growing attention involves the relationship between pharmaceutical agents and rare but serious adverse events, particularly in the context of long-term medication use. This pivot from general health principles to specific exposure concerns is exemplified by the transition from broad discussions of osteoporosis management to focused inquiries about the safety profile of bisphosphonate therapies. The shift requires a careful examination of how routine clinical exposures—such as those encountered in mass production settings or prolonged therapeutic regimens—may alter risk landscapes. By moving from the general to the specific, the discourse now centers on the potential for certain drug exposures to contribute to localized tissue complications, without delving into mechanistic pathways. This transition underscores the need for vigilance in monitoring occupational and therapeutic exposures, while maintaining the neutral, evidence-informed tone that characterizes responsible health communication.

Bridging to Fosamax: Understanding the Drug and Its Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation may include pain, swelling, infection, and exposed bone. Diagnosis typically involves clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition can occur spontaneously but is more commonly linked to invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms and Risk Factors for Fosamax-Associated ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has high turnover rates and is subject to frequent microtrauma from chewing, this suppression may impair the ability to repair microdamage and maintain bone health. Multiscale characterization of jawbone tissue has provided insights into its unique responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Evidence of Causation: Does Fosamax Cause ONJ?

Regarding causation, the evidence indicates that Fosamax can cause ONJ, as it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Warnings and Risk Management in Prescribing Information

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the risk-benefit assessment for individual patients requires careful consideration.

Causation Considerations for Affected Patients

For affected patients, causation-related considerations include the presence of known risk factors, duration of Fosamax use, and temporal relationship between drug exposure and ONJ onset. The timeline between exposure and documented harm can range from days to months after starting the drug, but ONJ may also occur after longer-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients with multiple risk factors, such as those undergoing dental procedures or receiving concomitant therapies like corticosteroids, may be at higher risk. The label emphasizes that ONJ can occur spontaneously, but it is generally associated with dental procedures or infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, establishing causation in individual cases requires a thorough evaluation of all contributing factors. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly in patients with additional risk factors. The prescribing information includes warnings and recommendations for risk mitigation, but the condition remains a serious potential adverse effect. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the risk of ONJ, especially in those undergoing dental procedures or with other predisposing conditions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing. Clinical presentation may include pain, swelling, infection, and exposed bone. Diagnosis typically involves clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis.

Does Fosamax cause osteonecrosis of the jaw?

Yes, evidence indicates that Fosamax can cause ONJ, as it has been reported in patients taking bisphosphonates, including Fosamax. The risk may increase with longer duration of exposure. The time to onset can vary from one day to several months. Most patients improve after discontinuing the drug, but recurrence may occur if rechallenged.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.